IGF-1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-30. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Nature Communications, 6, 7564. https://doi.org/10.1038/ncomms8564 J. Su, P. Wang, W. Zhou, M. Peydayesh, J. Zhou, T. Jin, F. Donat, C. Jin, L. Xia, K. Wang, F. Ren, P. Van der Meeren, F. Pelayo García de Arquer & R. Mezzenga (2024). Single-site iron-anchored amyloid hydrogels as catalytic platforms for alcohol detoxification. Nature Nanotechnology, 19(8), 1168–1177. https://doi.org/10.1038/s41565-024-01657-7 J. Zhou, S. Gowachirapant, C. Zeder, A. Wieczorek, J. Guth, I. Kutzli, S. Siol, F. von Meyenn, M. B. Zimmermann & R. Mezzenga (2025). Oat protein nanofibril–iron hybrids offer a stable, high-absorption iron delivery platform for iron fortification. Nature Food, 6, 1164–1175. https://doi.org/10.1038/s43016-025-01260-6 J. Adamcik & R. Mezzenga (2018). Amyloid polymorphism in the protein folding and aggregation energy landscape. Angewandte Chemie International Edition, 57(28), 8370–8382. https://doi.org/10.1002/anie.201713416 D. Xu, J. Zhou, W.L. Soon, I. Kutzli, A. Molière, S. Diedrich, M. Radiom, S. Handschin, B. Li, L. Li, S. J. Sturla, C. Y. Ewald, R. Mezzenga (2023). Food amyloid fibrils are safe nutrition ingredients based on in-vitro and in-vivo assessment. Nature Communications, 14(1), 6806. https://doi.org/10.1038/s41467-023-42486-x
== In germline cells == In 1957, André and Rouiller first coined the term "nuage". (French for "cloud"). Its amorphous and fibrous structure occurred in drawings as early as in 1933 (Risley). Today, the nuage is accepted to represent a characteristic, electrondense germ plasm organelle encapsulating the cytoplasmic face of the nuclear envelope of the cells destined to the germline fate. The same granular material is also known under various synonyms: dense bodies, mitochondrial clouds, yolk nuclei, Balbiani bodies, perinuclear P granules in Caenorhabditis elegans, germinal granules in Xenopus laevis, chromatoid bodies in mice, and polar granules in Drosophila. Molecularly, the nuage is a tightly interwoven network of differentially localized RNA-binding proteins, which in turn localize specific mRNA species for differential storage, asymmetric segregation (as needed for asymmetric cell division), differential splicing and/or translational control. The germline granules appear to be ancestral and universally conserved in the germlines of all metazoan phyla. Many germline granule components are part of the piRNA pathway and function to repress transposable elements.
The fact that the Government has not dared to challenge the nation to rise above itself, is one among many signs. [...] The war is, in fact, not being taken seriously. [...] How can any slacker be blamed when the Government itself is slack. Asquith's Liberal government was brought down in May 1915, due in particular to a crisis in inadequate artillery shell production and the protest resignation of Admiral Fisher over the disastrous Gallipoli Campaign against Turkey. Reluctant to face doom in an election, Asquith formed a new coalition government on 25 May, with the majority of the new cabinet coming from his own Liberal party and the Unionist (Conservative) party, along with a token Labour representation. The new government lasted a year and a half and was the last time Liberals controlled the government. The analysis of historian A. J. P. Taylor is that the British people were so deeply divided over numerous issues, but on all sides, there was growing distrust of the Asquith government. There was no agreement whatsoever on wartime issues. The leaders of the two parties realized that embittered debates in Parliament would further undermine popular morale and so the House of Commons did not once discuss the war before May 1915. Taylor argues:
Sources: en.wikipedia.org
=== Interpretation === Accurate interpretation takes a variety of factors into account, such as the thyroid hormones i.e. thyroxine (T4) and triiodothyronine (T3), current medical status (such as pregnancy), certain medications like propylthiouracil, temporal effects including circadian rhythm and hysteresis, and other past medical history.
About the same time as blotter paper, LSD came "Windowpane" (AKA "Clearlight"), which contained LSD inside a thin gelatin square a quarter of an inch (6 mm) across. LSD has been sold under a wide variety of often short-lived and regionally restricted street names, including Acid, Trips, Uncle Sid, Blotter, Lucy, Alice and doses, as well as names that reflect the designs on the sheets of blotter paper. Authorities have encountered the drug in other forms—including powder or crystal, and capsule.
== History == DART resulted from conversations between Laramee and Cody about the development of an atmospheric pressure ion source to replace the radioactive sources in handheld chemical weapons detectors. DART was developed in late 2002 to early 2003 by Cody and Laramee as a new atmospheric pressure ionization process, and a US patent application was filed in April 2003. Although the development of DART actually predated the desorption electrospray ionization (DESI) ion source, the initial DART publication did not appear until shortly after the DESI publication, and both ion sources were publicly introduced in back-to-back presentations by R. G. Cooks and R. B. Cody at the January 2005 ASMS Sanibel Conference. DESI and DART are considered as pioneer techniques in the field of ambient ionization, since they operate in the open laboratory environment and do not require sample pretreatment. In contrast to the liquid spray used by DESI, the ionizing gas from the DART ion source contains a dry stream containing excited state species.
Sources: en.wikipedia.org
Commodore Tim Hare, former Director of Nuclear Policy at the British Ministry of Defence, has described "sub-strategic use" as offering the Government "an extra option in the escalatory process before it goes for an all-out strategic strike which would deliver unacceptable damage". However, this sub-strategic capacity has been criticized as potentially increasing the "acceptability" of using nuclear weapons. Combined with the trend in the reduction in the worldwide nuclear arsenal as of 2007 is the warhead miniaturization and modernization of the remaining strategic weapons that is presently occurring in all the declared nuclear weapon states, into more "usable" configurations. The Stockholm International Peace Research Institute suggests that this is creating a culture where use of these weapons is more acceptable and therefore is increasing the risk of war, as these modern weapons do not possess the same psychological deterrent value as the large Cold-War era, multi-megaton warheads. In many ways, this present change in the balance of terror can be seen as the complete embracement of the switch from the 1950s Eisenhower doctrine of "massive retaliation" to one of "flexible response", which has been growing in importance in the US nuclear war fighting plan/SIOP every decade since. For example, the United States adopted a policy in 1996 of allowing the targeting of its nuclear weapons at non-state actors ("terrorists") armed with weapons of mass destruction.
WJ0679 is a small-molecule oxytocin receptor agonist and vasopressin receptor antagonist. It acts specifically as a very weak partial agonist of the oxytocin receptor (Ki = 422 nM; EC50Tooltip half-maximal effective concentration = 406 nM; EmaxTooltip maximal efficacy = 13%) and as an antagonist of the vasopressin V1A receptor (Ki = 105 nM; IC50Tooltip half-maximal inhibitory concentration = 2,203 nM), whereas no data were reported for the vasopressin V2 receptor. Despite its low activational efficacy at the oxytocin receptor, WJ0679 induces prosocial effects, including increased time spent in close physical contact and increased active social investigation, in rodents. The chemical synthesis of WJ0679 has been described. Along with its close analogue CA7, WJ0679 has the smallest chemical structure known for an oxytocin receptor agonist, with WJ0679 having about 60% of the molecular weight of LIT-001 and both WJ0679 and CA7 lacking LIT-001's tail component. Many analogues of WJ0679 and CA7 have been described. WJ0679 was first described in the scientific literature by a group including Michael Kassiou, Michael Bowen, Iain McGregor, and others at the University of Sydney in 2018. This group has founded a startup pharmaceutical company called Kinoxis Therapeutics and is developing small-molecule oxytocin-related drugs like KNX-100 and the KNX-200 series for potential medical use as of the 2020s.
=== Xen and final release (2015–2020) === The release of the Xen part of the game had been the most difficult, since the team wanted to redesign the levels to overcome the poor perception that they had in Half-Life's original release. The team said, "We want our version of Xen to feel like it really belongs with the rest of the game in terms of mechanics, cohesion and progression," while at the same time, they wanted "to push the boundaries and explore this unique and varied setting; to build an experience that feels both fresh and familiar to players from all walks of Half-Life veterancy." Developing their new version of Xen was a chicken-or-the-egg dilemma, as without level design it was difficult to develop art assets, and without art assets it was hard to come up with cohesive level designs. They also wanted to give more story elements there, such as why human scientists were studying the world of Xen in the first place, trying to capture the same type of world-building by level design that Valve had been able to with the first parts of Half-Life. They also significantly reworked the boss battles to be more challenging and representative of the area they had in mind. Ultimately, the team expanded out Xen from about a one-hour experience in the original Half-Life to four hours in Black Mesa.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.